
  
    
      
        Background_NNP
        
        Streptococcus_NNP pyogenes_NNS causes_VBZ a_DT
        variety_NN of_IN diseases_NNS in_IN man_NN ranging_VBG from_IN mild_JJ suppurative_JJ
        throat_NN and_CC skin_NN infections_NNS like_IN pharyngitis_NNS and_CC erysipelas_NNS
        to_TO severe_JJ invasive_JJ conditions_NNS such_JJ as_IN necrotizing_VBG fasciitis_NNS
        and_CC streptococcal_NN toxic_JJ shock_NN syndrome_NN [_NN 1_CD ]_NN ._. One_CD of_IN the_DT
        most_RBS widely_RB recognized_VBN putative_JJ streptococcal_NN virulence_NN
        factors_NNS is_VBZ the_DT oxygen-stable_JJ hemolysin_NN ,_, streptolysin_NN S_NNP
        (_( SLS_NNP )_) ._. Despite_IN the_DT ease_NN of_IN measuring_VBG SLS_NNP activity_NN the_DT
        precise_JJ molecular_JJ nature_NN of_IN the_DT toxin_NN is_VBZ not_RB known_VBN ._. This_DT is_VBZ
        due_JJ ,_, in_IN part_NN ,_, to_TO the_DT assembly_NN requirement_NN of_IN a_DT carrier_NN
        molecule_NN ,_, e_SYM ._. g_SYM ._. double_RB stranded_VBN RNA_NNP ,_, and_CC a_DT peptide_NN to_TO form_VB
        the_DT functional_JJ hemolysin_NN [_NN 2_CD ]_NN ._. Recent_JJ genetic_JJ and_CC
        immunochemical_JJ studies_NNS have_VBP clearly_RB identified_VBN the_DT 
        sagA_NN /_NN pel_NN gene_NN as_IN being_VBG responsible_JJ
        for_IN the_DT key_JJ peptide_NN component_NN of_IN SLS_NNP [_NN 3_CD 4_CD 5_CD 6_CD ]_NN ._.
        The_DT precise_JJ biological_JJ role_NN of_IN SLS_NNP in_IN streptococcal_NN
        infections_NNS remains_VBZ controversial_JJ [_NN 7_CD ]_NN ._. The_DT original_JJ
        analysis_NN of_IN the_DT 
        sagA_NN gene_NN demonstrated_VBN that_DT
        inactivation_NN of_IN the_DT gene_NN encoding_VBG the_DT polypeptide_NN component_NN
        of_IN SLS_NNP rendered_VBD the_DT organism_NN less_JJR virulent_NN in_IN a_DT
        dermonecrotic_JJ mouse_NN model_NN [_NN 3_CD ]_NN ._. In_IN a_DT related_VBN series_NN of_IN
        studies_NNS ,_, Li_NNP et_CC al_NN also_RB isolated_VBD a_DT mutant_JJ that_IN not_RB only_RB
        lacked_VBD SLS_NNP activity_NN but_CC also_RB affected_VBN other_JJ phenotypes_NNS [_NN 4_CD
        ]_NN ._. The_DT additional_JJ phenotypes_NNS included_VBD surface_NN M_NNP and_CC
        M-_NNP related_VBD protein_NN as_RB well_RB as_IN the_DT secreted_JJ cysteine_NN
        protease_NN ,_, streptococcal_NN pyrogenic_JJ exotoxin_NN B_NNP ,_, SpeB_NNP [_NN 4_CD ]_NN ._.
        The_DT disrupted_VBN gene_NN was_VBD termed_VBN 
        pel_NN (_( pleotrophic_JJ effect_NN locus_JJ )_) ._. In_IN
        isolate_VB CS_NNP 101_CD the_DT 
        pel_NN gene_NN acted_VBD as_IN a_DT transcriptional_NN
        regulator_NN [_NN 4_CD ]_NN while_IN in_IN an_DT M_NNP 6_CD isolate_VB it_PRP displayed_VBD effects_NNS
        on_IN secretion_NN and_CC membrane_NN anchoring_VBG [_NN 8_CD ]_NN ._. The_DT transposon_NN
        inserted_VBN in_IN the_DT 
        pel_NN gene_NN mapped_VBN to_TO the_DT promoter_NN
        region_NN of_IN the_DT previously_RB identified_VBN 
        sagA_NN gene_NN (_( SLS-associated_NNP gene_NN A_DT )_) ._.
        Since_IN the_DT same_JJ gene_NN is_VBZ disrupted_VBN in_IN all_DT of_IN the_DT studies_NNS we_PRP
        will_MD use_VB the_DT designation_NN 
        sagA_NN /_NN pel_NN throughout_IN to_TO define_VB this_DT
        regulatory_JJ region_NN that_WDT also_RB is_VBZ directly_RB related_VBN to_TO the_DT
        β-hemolytic_JJ phenotype_NN ._.
        In_IN this_DT study_NN we_PRP have_VBP further_RBR characterized_VBN the_DT 
        sagA_NN /_NN pel_NN mutant_JJ of_IN isolate_VB CS_NNP 101_CD and_CC
        report_NN that_IN it_PRP is_VBZ less_JJR virulent_NN than_IN the_DT wild_JJ type_NN
        organism_NN ._. The_DT loss_NN of_IN virulence_NN associated_VBN with_IN the_DT 
        sagA_NN /_NN pel_NN mutant_JJ can_MD be_VB reversed_VBN by_IN
        injection_NN of_IN this_DT mutant_JJ into_IN the_DT skin_NN of_IN mice_NNS and_CC
        recovering_VBG a_DT β-hemolytic_JJ positive_JJ variant_NN from_IN the_DT kidney_NN
        72_CD hours_NNS later_RB ._. This_DT kidney-recovered_JJ variant_NN restored_VBD SLS_NNP
        activity_NN ,_, and_CC M_NNP and_CC M-_NNP related_VBD protein_NN expression_NN but_CC not_RB
        SpeB_NNP or_CC streptokinase_NNP (_( SK_NNP )_) secretion_NN ._. This_DT change_NN in_IN
        phenotype_NN was_VBD achieved_VBN despite_IN the_DT continued_VBN presence_NN of_IN
        the_DT Tn_NNP 
        917_CD transposon_NN in_IN the_DT promoter_NN region_NN
        of_IN the_DT 
        sagA_NN /_NN pel_NN gene_NN ._.
      
      
        Results_NNS
        
          Selection_NN of_IN sagA_NN /_NN pelvariants_NNS by_IN biological_JJ
          pressures_NNS in_IN the_DT mouse_NN
          The_DT 
          sagA_NN /_NN pel_NN mutant_JJ of_IN isolate_VB CS_NNP 101_CD
          fails_VBZ to_TO express_VB β-hemolysin_JJ ,_, SpeB_NNP ,_, SK_NNP or_CC surface_NN M_NNP and_CC
          M-_NNP related_VBD proteins_NNS [_NN 4_CD ]_NN ._. Based_VBN on_IN prior_JJ studies_VBZ from_IN
          our_PRP$ laboratory_NN [_NN 9_CD 10_CD ]_NN ,_, we_PRP predicted_VBD that_IN this_DT isolate_VB
          would_MD be_VB avirulent_NN in_IN the_DT mouse_NN skin_NN air_NN sac_NN model_NN ._. To_TO
          test_VB this_DT possibility_NN ,_, two_CD groups_NNS of_IN six_CD mice_NNS were_VBD
          injected_VBN with_IN 2_CD ×_NN 10_CD 9_CD cfu_NN of_IN either_DT wild_JJ type_NN or_CC an_DT
          isogenic_JJ 
          sagA_NN /_NN pel_NN mutant_JJ isolate_VB and_CC the_DT
          mice_NNS observed_VBD over_IN a_DT 72_CD hour_NN period_NN ._. Surprisingly_RB ,_, at_IN the_DT
          conclusion_NN of_IN this_DT study_NN there_EX was_VBD no_DT statistically_RB
          significant_JJ difference_NN (_( p_NN >_NN 0_CD ._. 05_CD )_) between_IN the_DT mice_NNS
          injected_VBN with_IN the_DT wild_JJ type_NN isolate_VB and_CC the_DT 
          sagA_NN /_NN pel_NN mutant_JJ (_( data_NNS not_RB
          shown_VBN )_) ._.
          This_DT result_NN was_VBD reminiscent_NN of_IN an_DT earlier_JJR study_NN
          conducted_VBN by_IN our_PRP$ laboratory_NN using_VBG the_DT 
          mga_NN mutant_JJ of_IN isolate_VB 64_CD /_NN 14_CD [_NN 9_CD ]_NN ._.
          In_IN this_DT case_NN ,_, although_IN the_DT 
          mga_NN mutant_JJ failed_VBD to_TO express_VB M_NNP or_CC
          M-_NNP related_VBD proteins_NNS ,_, however_RB ,_, it_PRP was_VBD capable_JJ of_IN causing_VBG a_DT
          lethal_JJ infection_NN [_NN 9_CD ]_NN ._. Detailed_NNP analysis_NN of_IN this_DT system_NN
          indicated_VBD that_IN the_DT mouse_NN was_VBD capable_JJ of_IN selecting_VBG an_DT M_NNP
          protein_NN over-expressing_JJ variant_NN despite_IN the_DT presence_NN of_IN
          the_DT 
          mga_NN mutation_NN in_IN an_DT identical_JJ
          location_NN [_NN 9_CD ]_NN ._.
          To_TO determine_VB if_IN selection_NN for_IN a_DT phenotypic_JJ variant_NN was_VBD
          also_RB occurring_VBG with_IN the_DT 
          sagA_NN /_NN pel_NN mutant_JJ ,_, mice_NNS were_VBD injected_VBN
          in_IN a_DT skin_NN air_NN sac_NN and_CC recovered_VBD at_IN varying_VBG times_NNS post_NN
          infection_NN from_IN either_DT the_DT spleen_NN ,_, liver_NN or_CC kidney_NN ._. Mice_NNS
          were_VBD euthanized_JJ at_IN 4_CD ,_, 8_CD ,_, 12_CD ,_, 24_CD ,_, 48_CD and_CC 72_CD hours_NNS post_NN
          infection_NN with_IN 10_CD 9_CD cfu_NN ._. Since_IN the_DT study_NN was_VBD designed_VBN to_TO
          select_VB for_IN revertants_NNS or_CC phenotypic_JJ variants_NNS ,_, studies_NNS of_IN
          the_DT wild_JJ type_NN isolate_VB were_VBD not_RB included_VBN ._. At_IN each_DT time_NN
          point_NN ,_, three_CD mice_NNS were_VBD euthanized_JJ and_CC spleen_NN ,_, kidney_NN and_CC
          liver_NN tissue_NN samples_NNS were_VBD obtained_VBN ._. The_DT samples_NNS were_VBD
          homogenized_JJ in_IN sterile_JJ PBS_NNP and_CC aliquots_NNS plated_JJ on_IN blood_NN
          agar_NN plates_NNS containing_VBG erythromycin_NN ._. The_DT results_NNS of_IN these_DT
          studies_NNS are_VBP presented_VBN in_IN Table_NNP 1_CD ._.
          At_IN four_CD hours_NNS ,_, only_RB one_CD of_IN the_DT three_CD mice_NNS showed_VBD a_DT
          significant_JJ bacteremia_NN in_IN any_DT sample_NN tested_VBN ._. In_IN the_DT other_JJ
          two_CD mice_NNS ,_, three_CD of_IN four_CD sites_NNS were_VBD sterile_JJ ._. Within_IN eight_CD
          hours_NNS only_RB one_CD mouse_NN showed_VBD >_NN 10_CD cfu_NN in_IN any_DT sample_NN and_CC
          the_DT organisms_NNS were_VBD confined_VBN to_TO the_DT spleen_NN ._. At_IN 24_CD hours_NNS a_DT
          low_JJ level_NN of_IN bacteria_NNS were_VBD noted_VBN in_IN the_DT spleen_NN samples_NNS
          and_CC by_IN 48_CD hours_NNS all_DT mice_NNS were_VBD sterile_JJ at_IN all_DT sites_NNS
          tested_VBN ._. Surprisingly_RB ,_, at_IN 72_CD hours_NNS bacteria_NNS could_MD be_VB
          recovered_VBN from_IN the_DT spleen_NN ,_, kidney_NN and_CC liver_NN of_IN three_CD of_IN
          four_CD mice_NNS ._. It_PRP was_VBD of_IN interest_NN that_IN the_DT majority_NN of_IN
          recovered_VBD isolates_VBZ at_IN 72_CD hours_NNS post-infection_JJ were_VBD
          β-hemolytic_JJ (_( data_NNS not_RB shown_VBN )_) ._.
          All_DT of_IN these_DT isolates_VBZ were_VBD erythromycin-resistant_JJ
          indicating_VBG that_IN the_DT Tn_NNP 
          917_CD transposon_NN was_VBD still_RB present_JJ in_IN
          these_DT variants_NNS ._. No_DT mice_NNS died_VBD prior_RB to_TO 72_CD hours_NNS in_IN this_DT
          experiment_NN ._. The_DT β-hemolytic_JJ positive_JJ phenotype_NN of_IN these_DT
          recovered_VBN variants_NNS was_VBD stable_JJ for_IN over_IN ten_CD passages_NNS on_IN
          blood_NN agar_NN plates_NNS or_CC in_IN broth_NN (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          Analysis_NNP of_IN the_DT chromosomal_NN DNA_NNP of_IN the_DT
          sagA_NN /_NN pelmutant_NN and_CC kidney-recovered_JJ variants_NNS
          To_TO determine_VB whether_IN the_DT β-hemolytic_JJ positive_JJ 
          sagA_NN /_NN pel_NN variants_NNS recovered_VBD from_IN
          the_DT kidney_NN of_IN an_DT infected_JJ mouse_NN maintained_VBD the_DT Tn_NNP 
          917_CD transposon_NN in_IN the_DT original_JJ
          location_NN ,_, we_PRP performed_VBD XL-PCR_NNP and_CC Southern_NNP blot_NN analysis_NN
          as_RB well_RB as_IN sequencing_VBG the_DT region_NN near_IN the_DT Tn_NNP 
          917_CD insertion_NN using_VBG chromosomal_NN DNA_NNP
          from_IN the_DT parental_JJ 
          sagA_NN /_NN pel_NN strain_NN and_CC the_DT
          kidney-recovered_JJ isolates_VBZ as_IN templates_NNS ._. The_DT XL-PCR_NNP
          profile_NN of_IN the_DT parental_JJ 
          sagA_NN /_NN pel_NN mutant_JJ and_CC the_DT β-hemolytic_JJ
          kidney-recovered_JJ variants_NNS was_VBD identical_JJ (_( Fig_NNP ._. 1_LS A_DT )_) ._. In_IN
          addition_NN ,_, there_EX was_VBD no_DT difference_NN in_IN the_DT DNA_NNP sequence_NN
          around_IN the_DT transposon-_NN 
          sagA_NN /_NN pel_NN junction_NN between_IN the_DT
          original_JJ 
          sagA_NN /_NN pel_NN mutant_JJ and_CC the_DT
          kidney-recovered_JJ variant_NN (_( Fig_NNP ._. 1_LS B_NNP &_CC 1_CD C_NNP )_) ._. Southern_NNP
          blotting_VBG confirmed_VBN that_IN the_DT location_NN and_CC size_NN of_IN the_DT Tn_NNP 
          917_CD insertion_NN was_VBD unaltered_JJ in_IN the_DT
          kidney-recovered_JJ variant_NN compared_VBN to_TO the_DT parental_JJ strain_NN
          and_CC that_IN only_RB a_DT single_JJ Tn_NNP 
          917_CD transposon_NN was_VBD present_JJ (_( data_NNS
          not_RB shown_VBN )_) ._. Thus_RB the_DT restoration_NN of_IN β-hemolysis_JJ cannot_NN be_VB
          due_JJ to_TO loss_NN ,_, rearrangement_NN or_CC duplication_NN of_IN the_DT Tn_NNP 
          917_CD ._.
        
        
          Northern_JJ blot_NN and_CC primer_NN extension_NN analysis_NN of_IN
          sagA_NN /_NN pel_NN
          The_DT insertion_NN site_NN for_IN the_DT Tn_NNP 
          917_CD transposon_NN is_VBZ in_IN the_DT promoter_NN
          region_NN of_IN the_DT 
          sagA_NN /_NN pel_NN gene_NN and_CC no_DT 
          sagA_NN /_NN pel_NN message_NN was_VBD detected_VBN in_IN
          the_DT original_JJ mutant_JJ [_NN 4_CD ]_NN ._. RNA_NNP was_VBD isolated_VBN from_IN the_DT
          β-hemolytic_JJ positive_JJ kidney-recovered_JJ variant_NN and_CC the_DT
          wild_JJ type_NN isolate_VB and_CC analyzed_VBD for_IN 
          sagA_NN /_NN pel_NN message_NN by_IN Northern_NNP
          blotting_VBG ,_, (_( Fig_NNP ._. 2_LS )_) ._. A_DT 500_CD base_NN message_NN was_VBD detected_VBN in_IN
          both_DT the_DT wild_JJ type_NN and_CC kidney-recovered_JJ variants_NNS but_CC not_RB
          in_IN the_DT RNA_NNP isolated_VBD from_IN the_DT 
          sagA_NN /_NN pel_NN mutant_JJ (_( Fig_NNP ._. 2_LS )_) ._. In_IN
          contrast_NN to_TO previous_JJ reports_NNS [_NN 3_CD 4_CD 5_CD ]_NN a_DT second_JJ smaller_JJR
          transcript_NN was_VBD detected_VBN in_IN the_DT wild_JJ type_NN strain_NN (_( Fig_NNP ._. 2_LS ,_,
          lane_NN 1_CD -_: 2_LS )_) ._. This_DT transcript_NN was_VBD not_RB seen_VBN in_IN the_DT 
          sagA_NN /_NN pel_NN mutant_JJ or_CC kidney-recovered_JJ
          variants_NNS grown_VBN under_IN these_DT conditions_NNS (_( Fig_NNP ._. 2_LS ,_, lane_NN
          3_CD -_: 5_LS )_) ._.
          Primer_NNP extension_NN analysis_NN of_IN the_DT wild_JJ type_NN and_CC
          kidney-recovered_JJ variants_NNS demonstrated_VBN that_IN the_DT 
          sagA_NN /_NN pel_NN message_NN expressed_VBD in_IN the_DT
          kidney-recovered_JJ variant_NN had_VBD an_DT identical_JJ transcription_NN
          start_NN site_NN to_TO the_DT 500_CD base_NN message_NN present_JJ in_IN the_DT wild_JJ
          type_NN strain_NN (_( Fig_NNP ._. 3_LS )_) ._. The_DT second_JJ transcript_NN ,_, present_JJ only_RB
          in_IN the_DT RNA_NNP isolated_VBD from_IN the_DT wild_JJ type_NN isolate_VB (_( Fig_NNP ._. 3_LS ,_,
          lane_NN 1_LS )_) ,_, started_VBD 35_CD bases_NNS downstream_JJ of_IN the_DT longer_JJR
          transcript_NN ._. It_PRP is_VBZ not_RB clear_JJ whether_IN this_DT is_VBZ a_DT second_JJ
          transcription_NN start_NN site_NN or_CC a_DT processed_VBN form_NN of_IN the_DT
          larger_JJR transcript_NN ._. It_PRP is_VBZ interesting_JJ to_TO note_VB that_IN two_CD
          6_CD -_: base_NN palindromes_NNS are_VBP located_VBN immediately_RB downstream_JJ of_IN
          the_DT 5_CD '_POS -_: end_NN of_IN the_DT shorter_JJR transcript_NN and_CC a_DT 6_CD -_: base_NN
          inverted_JJ repeat_NN lies_VBZ just_RB upstream_RB of_IN the_DT 5_CD '_POS -_: end_NN of_IN the_DT
          larger_JJR transcript_NN (_( Fig_NNP ._. 3_LS lower_JJR panel_NN )_) ._.
        
        
          Analysis_NNP of_IN other_JJ sagA_NN /_NN pelphenotypes_NNS
          The_DT presence_NN of_IN a_DT 
          sagA_NN /_NN pel_NN transcript_NN is_VBZ consistent_JJ
          with_IN the_DT β-hemolytic_JJ phenotype_NN of_IN the_DT kidney-recovered_JJ
          variants_NNS ._. Previous_JJ studies_NNS have_VBP demonstrated_VBN that_IN the_DT
          inactivation_NN of_IN the_DT 
          sagA_NN /_NN pel_NN gene_NN product_NN also_RB effects_VBZ
          expression_NN of_IN other_JJ key_JJ streptococcal_NN products_NNS ,_, including_VBG
          surface_NN M_NNP proteins_NNS ,_, streptokinase_NNP (_( SK_NNP )_) and_CC the_DT secreted_JJ
          cysteine_NN protease_NN ,_, SpeB_NNP [_NN 4_CD ]_NN ._. Analysis_NNP of_IN SpeB_NNP ,_, SK_NNP and_CC
          M_NNP and_CC M-_NNP related_VBD proteins_NNS was_VBD conducted_VBN to_TO determine_VB if_IN
          restoration_NN of_IN the_DT expression_NN of_IN the_DT large_JJ 
          sagA_NN /_NN pel_NN transcript_NN also_RB reverted_VBN
          the_DT other_JJ phenotypes_NNS associated_VBN with_IN the_DT wild_JJ type_NN
          organism_NN ._.
          Expression_NNP of_IN surface_NN fibrinogen-binding_JJ M_NNP and_CC
          M-_NNP related_VBD proteins_NNS was_VBD monitored_VBN by_IN the_DT ability_NN of_IN intact_JJ
          bacteria_NNS to_TO bind_NN radiolabeled_JJ fibrinogen_NN ._. The_DT
          kidney-recovered_JJ mutant_JJ not_RB only_RB recovered_VBD fibrinogen_NN
          binding_JJ potential_NN ,_, that_WDT was_VBD lost_VBN when_WRB the_DT 
          sagA_NN /_NN pel_NN gene_NN was_VBD inactivated_JJ ,_, but_CC
          also_RB the_DT level_NN of_IN fibrinogen-binding_JJ exceeded_VBD that_IN of_IN the_DT
          wild_JJ type_NN isolate_VB (_( Fig_NNP ._. 4_LS A_DT )_) ._. Analysis_NNP of_IN culture_NN
          supernatants_NNS for_IN the_DT presence_NN of_IN SpeB_NNP (_( Fig_NNP ._. 4_LS B_NNP )_) or_CC SK_NNP
          (_( Fig_NNP ._. 4_LS C_NNP )_) indicated_VBD that_IN the_DT 
          sagA_NN /_NN pel_NN mutant_JJ and_CC the_DT
          kidney-recovered_JJ variant_NN displayed_VBD a_DT similar_JJ low_JJ level_NN of_IN
          expression_NN when_WRB compared_VBN to_TO the_DT wild_JJ type_NN ._. There_EX were_VBD no_DT
          significant_JJ changes_NNS in_IN fibronectin_NN binding_VBG among_IN any_DT of_IN
          the_DT variants_NNS tested_VBN (_( see_VB Table_NNP 2_LS )_) ._. Consequently_RB ,_,
          restoration_NN of_IN expression_NN of_IN the_DT larger_JJR 
          sagA_NN /_NN pel_NN transcript_NN (_( Fig_NNP ._. 3_LS )_) was_VBD
          not_RB sufficient_JJ to_TO revert_NN all_DT of_IN the_DT 
          sagA_NN /_NN pel_NN -_: associated_VBN phenotypes_NNS to_TO
          wild_JJ type_NN levels_NNS (_( see_VB Table_NNP 2_LS )_) ._.
        
        
          Restoration_NNP of_IN virulence_NN in_IN the_DT kidney-recovered_JJ
          pelmutants_NNS
          Based_VBN on_IN the_DT M_NNP and_CC M-_NNP related_VBD protein_NN phenotypic_JJ
          characteristics_NNS of_IN the_DT β-hemolytic_JJ positive_JJ
          kidney-recovered_JJ variant_NN of_IN the_DT 
          sagA_NN /_NN pel_NN mutant_JJ 
          in_IN vitro_NN ,_, we_PRP predicted_VBD this_DT
          variant_NN would_MD be_VB virulent_NN in_IN a_DT mouse_NN skin_NN infection_NN
          model_NN ._. To_TO test_VB this_DT prediction_NN the_DT kidney-recovered_JJ
          variant_NN ,_, the_DT wild_JJ type_NN and_CC the_DT original_JJ 
          sagA_NN /_NN pel_NN mutant_JJ were_VBD tested_VBN for_IN
          virulence_NN using_VBG the_DT skin_NN air_NN sac_NN model_NN ._. The_DT results_NNS
          present_JJ in_IN figure_NN 5_CD indicate_VBP that_IN the_DT kidney-recovered_JJ
          variant_NN was_VBD significantly_RB more_JJR virulent_NN than_IN the_DT 
          sagA_NN /_NN pel_NN mutant_JJ from_IN which_WDT it_PRP was_VBD
          originally_RB selected_VBN (_( p_NN =_SYM 0_CD ._. 018_CD )_) despite_IN not_RB secreting_VBG
          SpeB_NNP or_CC SK_NNP in_IN culture_NN (_( see_VB Table_NNP 2_LS )_) ._.
        
      
      
        Discussion_NNP
        Inactivation_NNP of_IN the_DT 
        sagA_NN /_NN pel_NN locus_JJ by_IN insertion_NN of_IN a_DT Tn_NNP 
        917_CD transposon_NN into_IN the_DT promoter_NN
        region_NN leads_VBZ to_TO decreased_VBN expression_NN of_IN SLS_NNP ,_, SpeB_NNP ,_, SK_NNP as_RB
        well_RB as_IN M_NNP and_CC M-_NNP related_VBD proteins_NNS [_NN 4_CD ]_NN and_CC reduced_VBN
        virulence_NN in_IN a_DT mouse_NN model_NN of_IN infection_NN using_VBG Cytodex_NNP beads_NNS
        [_NN 3_CD ]_NN ._. In_IN this_DT paper_NN we_PRP have_VBP shown_VBN that_IN this_DT mutation_NN also_RB
        leads_VBZ to_TO decreased_VBN or_CC delayed_VBN virulence_NN in_IN a_DT mouse_NN air-sac_JJ
        model_NN of_IN infection_NN ._. Although_IN virulence_NN of_IN the_DT 
        sagA_NN /_NN pel_NN mutant_JJ was_VBD decreased_VBN during_IN
        the_DT initial_JJ infection_NN period_NN ,_, viable_JJ bacteria_NNS could_MD be_VB
        isolated_VBN from_IN the_DT spleen_NN ,_, kidney_NN or_CC liver_NN 72_CD hours_NNS after_IN
        infection_NN in_IN the_DT skin_NN ._. What_WP was_VBD surprising_JJ was_VBD when_WRB
        cultured_JJ on_IN blood_NN agar_NN plates_NNS at_IN 37_CD °_NN C_NNP these_DT isolates_VBZ were_VBD
        β-hemolytic_JJ yet_RB remained_VBD erythromycin_NN resistant_JJ ._.
        In_IN this_DT study_NN we_PRP have_VBP analyzed_VBN a_DT representative_NN
        β-hemolytic_JJ positive_JJ kidney-recovered_JJ variant_NN ._. Direct_NNP
        genomic_JJ sequencing_VBG of_IN the_DT 
        sagA_NN /_NN pel_NN :_: :_: Tn_NNP 
        917_CD insertion_NN junction_NN in_IN these_DT
        kidney-recovered_JJ β-hemolysis_JJ positive_JJ variants_NNS established_VBN
        that_IN the_DT transposon_NN was_VBD present_JJ in_IN the_DT genome_NN in_IN exactly_RB
        the_DT same_JJ location_NN as_IN the_DT parental_JJ β-hemolytic_JJ negative_JJ 
        sagA_NN /_NN pel_NN mutant_JJ ._. Northern_JJ blot_NN and_CC
        primer_NN extension_NN analysis_NN confirmed_VBD that_IN the_DT 
        sagA_NN /_NN pel_NN gene_NN was_VBD transcribed_JJ in_IN the_DT
        β-hemolytic_JJ kidney-recovered_JJ variant_NN ,_, while_IN 
        sagA_NN /_NN pel_NN message_NN was_VBD not_RB seen_VBN in_IN the_DT
        parental_JJ β-hemolysis_JJ negative_JJ 
        sagA_NN /_NN pel_NN mutant_JJ ._. Since_IN the_DT 
        sagA_NN /_NN pel_NN promoter_NN was_VBD identical_JJ in_IN
        both_DT the_DT parental_JJ and_CC kidney-recovered_JJ isolates_VBZ we_PRP conclude_VBP
        that_IN the_DT Tn_NNP 
        917_CD was_VBD inserted_VBN into_IN a_DT positive_JJ
        regulatory_JJ site_NN and_CC not_RB into_IN an_DT essential_JJ promoter_NN
        sequence_NN ._.
        In_IN previous_JJ studies_NNS only_RB a_DT single_JJ 
        sagA_NN /_NN pel_NN transcript_NN were_VBD observed_VBN [_NN 3_CD
        4_CD 5_CD ]_NN ._. However_RB ,_, in_IN this_DT study_NN we_PRP have_VBP identified_VBN two_CD 
        sagA_NN /_NN pel_NN transcripts_NNS present_JJ in_IN
        approximately_RB equal_JJ concentration_NN in_IN the_DT wild_JJ type_NN parent_NN
        (_( Figure_NN 2_LS )_) ._. We_PRP do_VBP not_RB know_VB if_IN this_DT second_JJ shorter_JJR
        transcript_NN represents_VBZ a_DT second_JJ transcription_NN start_NN site_NN or_CC
        is_VBZ a_DT processed_VBN form_NN of_IN the_DT larger_JJR transcript_NN ._. What_WP is_VBZ
        intriguing_JJ is_VBZ that_IN only_RB the_DT larger_JJR transcript_NN is_VBZ present_JJ in_IN
        the_DT β-hemolysis_JJ positive_JJ kidney-recovered_JJ variant_NN ._. This_DT
        result_NN would_MD be_VB consistent_JJ with_IN the_DT hypothesis_NNS that_WDT 
        sagA_NN /_NN pel_NN has_VBZ two_CD transcriptional_NN
        start_NN sites_NNS and_CC expression_NN from_IN only_RB one_CD site_NN is_VBZ restored_VBN
        after_IN mouse_NN selection_NN ._. Other_JJ 
        S_NNP ._. pyogenes_NNS regulators_NNS have_VBP been_VBN
        shown_VBN to_TO have_VB multiple_JJ transcription_NN start_NN sites_NNS that_WDT are_VBP
        differentially_RB regulated_VBN ._. For_IN example_NN ,_, Mga_NNP ,_, a_DT
        transcriptional_NN activator_NN of_IN M_NNP and_CC M-_NNP related_VBD proteins_NNS ,_, also_RB
        has_VBZ two_CD transcription_NN start_NN sites_NNS that_WDT are_VBP independently_RB
        regulated_VBN [_NN 11_CD ]_NN and_CC two_CD distinct_JJ transcription_NN start_NN sites_NNS
        are_VBP associated_VBN with_IN expression_NN of_IN the_DT streptokinase_NNP gene_NN [_NN
        12_CD 13_CD 14_CD 15_CD ]_NN ._.
        The_DT strain_NN CS_NNP 101_CD 
        sagA_NN /_NN pel_NN :_: :_: Tn_NNP 
        917_CD has_VBZ previously_RB been_VBN rendered_VBN
        β-hemolytic_JJ negative_NN by_IN a_DT transposon_NN insertion_NN ._. To_TO recover_VB
        a_DT β-hemolysis_JJ positive_JJ variant_NN ,_, from_IN the_DT mouse_NN kidney_NN ,_, with_IN
        the_DT transposon_NN in_IN its_PRP$ original_JJ position_NN was_VBD unexpected_JJ ._.
        This_DT result_NN indicated_VBD additional_JJ levels_NNS of_IN regulation_NN of_IN
        the_DT β-hemolysis_JJ phenotype_NN could_MD be_VB selected_VBN by_IN biological_JJ
        pressures_NNS in_IN the_DT mouse_NN ._. The_DT selected_VBN β_NN hemolysis_NNS positive_JJ
        variant_NN was_VBD stable_JJ and_CC retained_VBD this_DT phenotype_NN even_RB after_IN
        repeated_VBN passage_NN on_IN laboratory_NN media_NNS in_IN the_DT absence_NN of_IN any_DT
        additional_JJ selective_JJ biological_JJ pressures_NNS ._.
        The_DT mouse_NN selection_NN process_NN results_NNS not_RB only_RB in_IN the_DT
        restoration_NN of_IN a_DT β-hemolytic_JJ positive_JJ phenotype_NN ,_, but_CC also_RB
        restored_VBD some_DT ,_, but_CC not_RB all_DT ,_, of_IN the_DT phenotypes_NNS known_VBN to_TO be_VB
        regulated_VBN by_IN 
        sagA_NN /_NN pel_NN [_NN 4_CD ]_NN ._. For_IN example_NN ,_,
        fibrinogen-binding_JJ M_NNP and_CC M-_NNP related_VBD protein_NN expression_NN was_VBD
        restored_VBN ;_: however_RB secretion_NN of_IN the_DT cysteine_NN protease_NN ,_, SpeB_NNP ,_,
        or_CC SK_NNP was_VBD not_RB ._. Previous_JJ studies_NNS from_IN our_PRP$ laboratory_NN have_VBP
        consistently_RB demonstrated_VBN loss_NN of_IN the_DT SpeB_NNP phenotype_NN in_IN 
        S_NNP ._. pyogenes_NNS isolates_VBZ injected_VBN in_IN a_DT
        skin_NN air_NN sac_NN and_CC recovered_VBD from_IN the_DT organs_NNS of_IN lethally_RB
        infected_JJ mice_NNS [_NN 10_CD 16_CD ]_NN ._. This_DT selection_NN was_VBD not_RB associated_VBN
        with_IN loss_NN of_IN β-hemolysis_JJ but_CC was_VBD associated_VBN with_IN
        over-expression_JJ of_IN M_NNP and_CC M-_NNP related_VBD proteins_NNS ,_, which_WDT in_IN turn_NN
        are_VBP predictive_JJ of_IN the_DT invasive_JJ potential_NN of_IN the_DT organism_NN in_IN
        a_DT skin_NN infection_NN model_NN [_NN 16_CD ]_NN ._. Based_VBN on_IN the_DT phenotypic_JJ
        characteristics_NNS of_IN the_DT kidney-recovered_JJ variant_NN
        (_( β-hemolytic_JJ positive_NN ,_, M_NNP and_CC M-_NNP related_VBD protein_NN positive_JJ and_CC
        SpeB_NNP negative_JJ )_) we_PRP predicted_VBD that_IN this_DT variant_NN would_MD be_VB as_IN
        virulent_NN or_CC more_JJR virulent_NN than_IN the_DT wild_JJ type_NN organism_NN in_IN
        the_DT mouse_NN skin_NN infection_NN model_NN ._. This_DT prediction_NN was_VBD tested_VBN
        experimentally_RB and_CC the_DT β-hemolysis_JJ positive_JJ 
        sagA_NN /_NN pel_NN variant_NN was_VBD found_VBN to_TO be_VB as_RB
        virulent_NN as_IN the_DT wild_JJ type_NN isolate_VB in_IN the_DT skin_NN infection_NN
        model_NN (_( see_VB figure_NN 5_LS )_) ._.
        The_DT genetic_JJ event_NN (_( s_VBZ )_) associated_VBN with_IN the_DT selection_NN of_IN a_DT
        virulent_NN variant_NN of_IN the_DT 
        sagA_NN /_NN pel_NN mutant_JJ without_IN changing_VBG the_DT
        site_NN or_CC orientation_NN of_IN the_DT Tn_NNP 
        917_CD transposon_NN was_VBD reminiscent_NN of_IN
        earlier_JJR studies_NNS from_IN our_PRP$ laboratory_NN testing_VBG the_DT virulence_NN
        of_IN 
        mga_NN mutants_NNS of_IN isolate_VB 64_CD /_NN 14_CD [_NN 9_CD ]_NN ._.
        In_IN that_DT study_NN ,_, injection_NN of_IN an_DT 
        mga_NN mutant_JJ ,_, that_WDT failed_VBD to_TO express_VB
        any_DT detectable_JJ surface_NN M_NNP or_CC M-_NNP related_VBD protein_NN ,_, lead_VB to_TO
        selection_NN of_IN 
        mga_NN variants_NNS over-expressing_JJ M_NNP and_CC
        M-_NNP related_VBD proteins_NNS that_WDT could_MD be_VB recovered_VBN from_IN the_DT spleen_NN
        following_VBG a_DT lethal_JJ skin_NN infection_NN ._. This_DT reversion_NN of_IN the_DT M_NNP
        and_CC M-_NNP related_VBD protein_NN phenotype_NN occurred_VBD without_IN any_DT change_NN
        in_IN the_DT position_NN or_CC orientation_NN of_IN the_DT
        spectinomycin-resistance_JJ cassette_NN inserted_VBN into_IN the_DT 
        mga_NN gene_NN to_TO create_VB the_DT original_JJ
        mutant_JJ [_NN 9_CD ]_NN ._.
        Taken_VBN together_RB ,_, these_DT studies_NNS suggest_VBP a_DT complex_JJ network_NN
        of_IN positive_JJ and_CC negative_JJ regulatory_JJ pathways_NNS controlling_VBG
        key_JJ virulence_NN genes_NNS in_IN 
        S_NNP ._. pyogenes_NNS that_WDT can_MD be_VB activated_VBN or_CC
        inactivated_JJ in_IN response_NN to_TO certain_JJ biological_JJ pressures_NNS in_IN
        the_DT infected_JJ host_NN ._. Analysis_NNP of_IN the_DT selected_VBN phenotypes_NNS
        recovered_VBD following_VBG mouse_NN passage_NN cannot_NN be_VB explained_VBN by_IN
        the_DT activities_NNS of_IN any_DT known_VBN regulator_NN or_CC combination_NN of_IN
        regulators_NNS e_SYM ._. g_SYM ._. 
        mga_NN [_NN 9_CD 17_CD 18_CD 19_CD 20_CD 21_CD 22_CD 23_CD 24_CD ]_NN ,_, 
        nra_NN [_NN 25_CD ]_NN ,_, 
        CsrRS_NNP /_NN CovRS_NNP [_NN 26_CD 27_CD 28_CD 29_CD ]_NN ,_, 
        sagA_NN /_NN pel_NN [_NN 4_CD ]_NN 
        rofA_NN [_NN 30_CD 31_CD 32_CD ]_NN ,_, 
        rgg_NN [_NN 33_CD 34_CD 35_CD ]_NN 
        ,_, fas_NNS X_NNP [_NN 36_CD ]_NN or_CC 
        luxS_NN [_NN 37_CD 38_CD ]_NN ._.
        It_PRP is_VBZ unknown_JJ if_IN there_EX is_VBZ a_DT regulator_NN or_CC a_DT series_NN of_IN
        regulators_NNS that_WDT are_VBP inactivated_JJ or_CC activated_VBN after_IN passage_NN
        through_IN the_DT mouse_NN ;_: however_RB ,_, it_PRP is_VBZ clear_JJ that_IN key_JJ virulence_NN
        factors_NNS are_VBP under_IN a_DT more_RBR complex_JJ pattern_NN of_IN regulation_NN than_IN
        previously_RB envisaged_VBD ._. In_IN related_VBN studies_NNS ,_, the_DT selection_NN of_IN
        stable_JJ variants_NNS of_IN either_DT wild_JJ type_NN or_CC mutant_JJ 
        S_NNP ._. pyogenes_NNS isolates_VBZ was_VBD not_RB
        consistently_RB observed_VBD when_WRB the_DT organism_NN was_VBD injected_VBN i_NNP ._. p_NN ._. [_NN
        39_CD ]_NN ._. This_DT may_MD relate_VB to_TO either_CC the_DT presence_NN of_IN unique_JJ
        host_NN factors_NNS at_IN the_DT skin_NN infection_NN site_NN or_CC to_TO the_DT kinetics_NNS
        of_IN clearance_NN of_IN the_DT organisms_NNS ._. In_IN studies_NNS using_VBG a_DT tissue_NN
        chamber_NN model_NN ,_, Kotb_NNP and_CC colleagues_NNS have_VBP noted_VBN changes_NNS in_IN
        expression_NN of_IN key_JJ virulence_NN factors_NNS as_IN a_DT function_NN of_IN time_NN [_NN
        40_CD ]_NN ._. Thus_RB ,_, it_PRP is_VBZ possible_JJ that_IN the_DT 
        in_IN vivo_NN events_NNS leading_VBG to_TO selection_NN
        of_IN stable_JJ 
        S_NNP ._. pyogenes_NNS variants_NNS may_MD require_VB a_DT
        dynamic_JJ interaction_NN with_IN the_DT host_NN and_CC that_IN only_RB under_IN
        certain_JJ experimental_JJ conditions_NNS will_MD the_DT stable_JJ variant_NN
        population_NN be_VB recovered_VBN ._.
        The_DT unique_JJ biological_JJ pressures_NNS associated_VBN with_IN
        infection_NN in_IN the_DT skin_NN and_CC persistence_NN in_IN the_DT systemic_JJ
        circulation_NN seems_VBZ to_TO consistently_RB select_VB stable_JJ variants_NNS
        which_WDT over-express_JJ key_JJ surface_NN M_NNP and_CC M-_NNP related_VBD proteins_NNS ._.
        Organisms_NNP selected_VBD in_IN this_DT model_NN are_VBP consistently_RB negative_JJ
        for_IN SpeB_NNP secretion_NN ._. Selection_NN of_IN SpeB_NNP negative_JJ variants_NNS
        have_VBP also_RB been_VBN noted_VBN following_VBG sequential_NN human_JJ blood_NN
        passage_NN of_IN isolates_VBZ or_CC in_IN a_DT mouse_NN skin_NN infection_NN model_NN [_NN 39_CD
        41_CD ]_NN ._. This_DT selective_JJ pressure_NN can_MD also_RB be_VB associated_VBN with_IN
        enhanced_JJ capsular_NN expression_NN in_IN SpeB_NNP negative_JJ variants_NNS [_NN 42_CD
        ]_NN ._.
        Several_JJ bacteriophage_NN and_CC transposons_NNS were_VBD identified_VBN in_IN
        the_DT 
        S_NNP ._. pyogenes_NNS genome_NN [_NN 43_CD ]_NN as_RB well_RB as_IN
        a_DT number_NN of_IN potential_JJ two-component_JJ regulatory_JJ systems_NNS
        whose_WP$ precise_JJ function_NN remains_VBZ to_TO be_VB elucidated_JJ ._. The_DT
        biological_JJ selection_NN of_IN phenotypic_JJ revertants_NNS of_IN variants_NNS
        of_IN 
        S_NNP ._. pyogenes_NNS from_IN populations_NNS with_IN
        defined_VBN mutations_NNS in_IN key_JJ regulators_NNS or_CC promoter_NN regions_NNS of_IN
        putative_JJ virulence_NN genes_NNS is_VBZ likely_JJ to_TO provide_VB key_JJ insights_NNS
        into_IN the_DT pathogenesis_NNS of_IN host-bacterial_JJ interactions_NNS ._.
      
      
        Conclusions_NNP
        Selection_NN of_IN β_NN hemolysis_NNS positive_JJ variants_NNS from_IN a_DT 
        sagA_NN /_NN pel_NN mutant_JJ of_IN 
        S_NNP ._. pyogenes_NNS isolate_VBP CS_NNP 101_CD were_VBD
        identified_VBN ._. This_DT change_NN in_IN phenotype_NN occurred_VBD despite_IN the_DT
        presence_NN of_IN the_DT Tn_NNP 
        917_CD transposon_NN in_IN an_DT identical_JJ
        position_NN in_IN both_DT the_DT β_NN hemolysis_NNS negative_JJ mutant_JJ and_CC the_DT β_NN
        hemolysis_NNS positive_JJ selected_VBN variant_NN ._. The_DT ability_NN of_IN
        biological_JJ pressures_NNS in_IN the_DT mouse_NN to_TO select_VB stable_JJ variants_NNS
        of_IN S_NNP ._. pyogenes_NNS expressing_VBG different_JJ patterns_NNS of_IN virulence_NN
        factors_NNS suggest_VBP the_DT existence_NN of_IN more_JJR complex_JJ regulatory_JJ
        pathway_NN than_IN is_VBZ currently_RB envisaged_VBN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Chemicals_NNS ,_, Bacteria_NNP and_CC Media_NNP
          The_DT bacteria_NNS used_VBN in_IN this_DT study_NN were_VBD the_DT opacity_NN
          factor_NN positive_JJ M_NNP 49_CD 
          Streptococcus_NNP pyogenes_NNS isolate_VBP
          CS_NNP 101_CD and_CC an_DT isogenic_JJ β-hemolytic_JJ negative_JJ variant_NN
          generated_VBN by_IN transposon_NN mutagenesis_NNS ,_, CS_NNP 101_CD 
          sagA_NN /_NN pel_NN :_: :_: Tn_NNP 
          917_CD [_NN 4_CD ]_NN ._. Todd-_NNP Hewitt_NNP broth_NN
          containing_VBG 0_CD ._. 3_CD %_NN yeast_NN extract_NN (_( THY_NNP )_) was_VBD obtained_VBN from_IN
          DIFCO_NNP (_( Detroit_NNP MI_NNP )_) ._. Blood_NNP agar_NN plates_NNS were_VBD obtained_VBN from_IN
          BBL_NNP (_( Fisher_NNP ,_, Chicago_NNP ,_, IL_NNP )_) ._.
        
        
          Mouse_NNP skin_NN air_NN sac_NN procedure_NN
          A_DT skin_NN air_NN sac_NN model_NN was_VBD used_VBN to_TO compare_VB the_DT virulence_NN
          of_IN isolate_VB CS_NNP 101_CD and_CC paired_VBN isogenic_JJ mutants_NNS [_NN 9_CD ]_NN ._.
          Briefly_NNP an_DT air-_NN and_CC liquid-tight_JJ connective_JJ tissue_NN pouch_NN
          was_VBD generated_VBN on_IN the_DT back_NN of_IN female_JJ ,_, six_CD week_NN old_JJ ,_,
          outbred_JJ CD_NNP 1_CD mice_NNS (_( Charles_NNP River_NNP ,_, Portage_NNP ,_, MI_NNP )_) by_IN slow_JJ
          dermal_NN injection_NN of_IN 0_CD ._. 9_CD mL_NN of_IN air_NN via_IN an_DT 0_CD ._. 4_CD mm_NN needle_NN on_IN
          a_DT 1_CD ._. 0_CD mL_NN syringe_NN ._. The_DT syringe_NN containing_VBG the_DT air_NN also_RB
          contained_VBD 0_CD ._. 1_CD mL_NN of_IN an_DT appropriately_RB diluted_VBN suspension_NN
          of_IN 
          S_NNP ._. pyogenes_NNS ._. Mice_NNS were_VBD provided_VBN
          with_IN food_NN and_CC water_NN ad_NN libitum_NN ._. For_IN selection_NN of_IN
          bacterial_JJ variants_NNS ,_, experiments_NNS were_VBD continued_VBN for_IN 72_CD
          hours_NNS post-infection_JJ ._. For_IN virulence_NN studies_NNS death_NN was_VBD
          used_VBN as_IN the_DT endpoint_NN and_CC at_IN 144_CD hours_NNS post-infection_JJ the_DT
          experiments_NNS terminated_VBD ._. For_IN bacteremia_NN studies_NNS surviving_VBG
          animals_NNS were_VBD euthanized_JJ at_IN the_DT times_NNS stated_VBN ._. Spleen_NNP ,_,
          kidney_NN and_CC a_DT section_NN of_IN the_DT liver_NN was_VBD removed_VBN from_IN the_DT
          animals_NNS ._. The_DT tissue_NN samples_NNS were_VBD homogenized_JJ in_IN 1_CD mL_NN of_IN
          sterile_JJ 10_CD mM_NN PBS_NNP ,_, pH_NN 7_CD ._. 4_CD ._. An_DT 100_CD μL_NN aliquot_NN was_VBD cultured_JJ
          on_IN blood_NN agar_NN plates_NNS to_TO determine_VB if_IN 
          S_NNP ._. pyogenes_NNS were_VBD present_JJ ._. All_DT
          animal_NN studies_NNS were_VBD conducted_VBN in_IN accordance_NN with_IN
          protocols_NNS approved_VBN by_IN the_DT Medical_NNP College_NNP of_IN Ohio_NNP 's_POS
          Institutional_NNP Animal_NNP Use_NNP and_CC Care_NNP Committee_NNP ._.
        
        
          Southern_JJ blot_NN analysis_NN and_CC XL-PCR_NNP
          Analysis_NNP of_IN chromosomal_NN DNA_NNP for_IN the_DT presence_NN of_IN Tn_NNP 
          917_CD transposon_NN insertion_NN was_VBD
          carried_VBN out_IN as_IN described_VBN previously_RB [_NN 4_CD ]_NN ._.
          XL-PCR_NNP was_VBD performed_VBN using_VBG GeneAmp_NNP XL_NNP PCR_NNP kit_NN (_( PE_NNP
          Applied_NNP Biosystems_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP )_) ._.
        
        
          DNA_NNP Sequencing_NNP
          Chromosomal_NNP DNA_NNP was_VBD isolated_VBN as_IN described_VBN previously_RB [_NN
          44_CD ]_NN ._. Genomic_NNP DNA_NNP sequencing_VBG was_VBD carried_VBN out_IN on_IN an_DT
          Applied_NNP Biosystems_NNP 310_CD Genetic_NNP Analyzer_NNP (_( PE_NNP /_NN Applied_NNP
          Biosystems_NNP )_) using_VBG a_DT big_JJ dye_NN terminator_NN cycle_NN sequencing_VBG
          ready_JJ reaction_NN kit_NN (_( PE_NNP /_NN Applied_NNP Biosystems_NNP )_) according_VBG to_TO
          the_DT manufacturer_NN 's_POS specifications_NNS ._. The_DT oligonucleotide_NN
          5_CD '_POS -_: ATAAATGGACCGCATATTGA-_NNP 3_CD '_POS (_( corresponding_JJ to_TO the_DT DNA_NNP
          sequence_NN just_RB downstream_JJ of_IN the_DT SagA_NNP /_NN Pel_NNP open_JJ reading_NN
          frame_NN )_) ,_, and_CC 5_CD '_POS -_: ATAAATGGACCGCATATTGA-_NNP 3_CD '_POS (_( corresponding_JJ to_TO
          the_DT region_NN from_IN the_DT right_JJ end_NN of_IN the_DT Tn_NNP 
          917_CD insertion_NN )_) were_VBD used_VBN as_IN primers_NNS
          for_IN the_DT sequencing_VBG reaction_NN ._. The_DT resulting_VBG DNA_NNP sequences_NNS
          was_VBD compared_VBN using_VBG blast_NN 2_CD for_IN pair_NN wise_JJ comparisons_NNS ._.
          http_NN :_: /_NN /_NN www_NN ._. ncbi_NN ._. nlm_NN ._. nih_NN ._. gov_NN /_NN blast_NN /_NN Blast_NNP ._. cgi_NN
        
        
          Northern_JJ blot_NN analysis_NN
          RNA_NNP was_VBD prepared_VBN from_IN wild_JJ type_NN CS_NNP 101_CD wt_NN ,_, 
          CS_NNP 101_CD sagA_NN /_NN pel_NN :_: :_: Tn_NNP 
          917_CD and_CC 
          CS_NNP 101_CD sagA_NN /_NN pel_NN :_: :_: Tn_NNP 
          917_CD kidney-recovered_JJ (_( KR_NNP )_) variants_NNS
          grown_VBN overnight_JJ (_( 37_CD °_NN C_NNP 10_CD %_NN CO_NNP 
          2_LS )_) in_IN 40_CD ml_NN THY_NNP media_NNS ._. The_DT bacteria_NNS
          were_VBD harvested_VBN 8_CD hours_NNS post-exponential_JJ phase_NN by_IN
          centrifugation_NN (_( 5_CD min_NN ,_, 4000_CD g_SYM ,_, 4_CD °_NN C_NNP )_) and_CC resuspended_JJ in_IN
          500_CD μL_NN of_IN cell_NN lysis_NNS buffer_NN (_( 25_CD %_NN glucose_NN ,_, 10_CD mM_NN EDTA_NNP ,_, 100_CD
          mM_NN Tris_NNP pH_NN 7_CD ._. 0_CD )_) ._. 400_CD μL_NN of_IN a_DT solution_NN containing_VBG 4_CD mg_NN /_NN mL_NN
          lysosyme_NN (_( Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_, MO_NNP ._. )_) and_CC mutanolysin_NN (_( 20_CD μg_NN )_) ,_,
          was_VBD added_VBN and_CC incubated_JJ for_IN 20_CD minutes_NNS at_IN 37_CD °_NN C_NNP ._. The_DT
          bacteria_NNS were_VBD sedimented_JJ by_IN centrifugation_NN and_CC
          resuspended_JJ in_IN 3_CD mL_NN Trizol_NNP (_( Gibco_NNP ,_, Rockville_NNP ,_, MD_NNP )_) ._. RNA_NNP
          was_VBD isolated_VBN according_VBG to_TO the_DT manufacturer_NN 's_POS
          instructions_NNS ._. The_DT RNA_NNP concentration_NN was_VBD determined_VBN
          spectrophotometrically_RB by_IN measuring_VBG absorbance_NN at_IN 260_CD nm_NN ._.
          RNA_NNP was_VBD electrophoresed_JJ in_IN a_DT 1_CD %_NN agarose_NN gel_NN (_( Molecular_NNP
          Biology_NNP Certified_NNP Agarose_NNP ,_, Biorad_NNP ,_, Hercules_NNP ,_, CA_NNP )_)
          containing_VBG 0_CD ._. 66_CD M_NNP formaldehyde_NN in_IN 1_CD ×_NN MOPS_NNP
          (_( 3_CD -_: (_( N-_NNP morpholino_NN )_) -_: propanesulfonic_JJ acid_NN )_) buffer_NN ._. Following_VBG
          electrophoresis_NNS ,_, RNA_NNP was_VBD transferred_VBN to_TO a_DT nylon_NN membrane_NN
          (_( Hybond-_NNP N_NNP +_NN ,_, Millipore_NNP ,_, Bedford_NNP ,_, MA_NNP )_) according_VBG to_TO the_DT
          manufacturer_NN 's_POS instructions_NNS ,_, and_CC hybridized_JJ with_IN
          digoxigen-d_JJ UTP-labeled_NNP probe_NN as_IN described_VBN previously_RB [_NN 4_CD
          ]_NN ._. The_DT primers_NNS used_VBN to_TO generate_VB the_DT probe_NN were_VBD :_:
          5_CD '_POS -_: GGAATTCACCTGCTAATTACCTGA-_NNP 3_CD '_POS and_CC
          5_CD '_POS -_: CGCGGATCCGTTTACACATAGTTATTGATAGAATCT-_NNP 3_CD '_''
        
        
          Primer_NNP extension_NN
          The_DT 5_CD '_POS -_: end_NN of_IN the_DT 
          sagA_NN /_NN pel_NN mRNA_NN was_VBD determined_VBN by_IN the_DT
          extension_NN of_IN the_DT 5_CD '_POS -_: end_NN 32_CD P-_NNP labeled_VBD oligonucleotides_NNS
          5_CD '_POS -_: ACCTTATTTTAAAAATAAAGTTAA-_NNP 3_CD '_POS following_VBG the_DT method_NN of_IN
          Sambrook_NNP [_NN 45_CD ]_NN ._. Oligonucleotides_NNP were_VBD labeled_VBN with_IN [_NN γ-_NN
          32_CD P_NN ]_NN ATP_NNP (_( 10_CD mCi_NN /_NN mL_NN in_IN aqueous_JJ solution_NN )_) (_( Amersham_NNP ,_,
          Arlington_NNP Heights_NNP ,_, IL_NNP )_) and_CC T_NN 4_CD polynucleotide_NN kinase_NN
          (_( Gibco_NNP BRL_NNP Life_NNP Technologies_NNPS ,_, Rockville_NNP ,_, MD_NNP )_) ._. SequiTherm_NNP
          EXCEL_NNP II_NNP DNA_NNP sequencing_VBG kit_NN (_( Epicentre_NNP Technologies_NNPS ,_,
          Madison_NNP ,_, WI_NNP )_) was_VBD used_VBN according_VBG to_TO the_DT manufacturer_NN 's_POS
          instruction_NN for_IN the_DT corresponding_JJ sequencing_VBG reaction_NN
          using_VBG the_DT same_JJ primer_NN ._.
        
        
          Streptokinase_NNP Assay_NNP
          Streptokinase_NNP activity_NN was_VBD measured_VBN as_IN described_VBN
          previously_RB [_NN 46_CD ]_NN ._. Briefly_NNP ,_, aliquots_NNS of_IN culture_NN
          supernatants_NNS (_( 100_CD μL_NN )_) were_VBD mixed_VBN with_IN either_DT 1_CD μg_NN of_IN
          purified_JJ human_JJ plasminogen_NN or_CC buffer_NN ._. The_DT synthetic_JJ
          chromogenic_JJ substrate_NN ,_, S_NNP 2251_CD
          (_( H-D-V_NNP al-_NN Leu-_NNP Lys-paranitroanilide_NNP )_) obtained_VBN from_IN Kabi_NNP
          Pharmacia_NNP (_( Franklin_NNP ,_, OH_NNP )_) ,_, was_VBD added_VBN to_TO a_DT final_JJ
          concentration_NN of_IN 400_CD μM_NN ._. Plasmin_NNP generation_NN was_VBD
          quantified_VBN by_IN measuring_VBG product_NN absorbance_NN at_IN 405_CD nm_NN ._.
        
        
          Cysteine_NNP endopetidase_NN assay_NN
          Cysteine_NNP protease_NN activity_NN present_JJ in_IN culture_NN
          supernatants_NNS was_VBD assayed_JJ as_IN described_VBN [_NN 47_CD ]_NN ._. Briefly_NNP ,_,
          50_CD μL_NN of_IN culture_NN supernatant_NN with_IN or_CC without_IN 0_CD ._. 1_CD μM_NN
          dithiothreitol_NN ,_, was_VBD added_VBN to_TO the_DT wells_NNS of_IN a_DT microtiter_NN
          plate_NN ._. Following_VBG incubation_NN for_IN 30_CD minutes_NNS at_IN 37_CD °_NN C_NNP 150_CD μL_NN
          of_IN the_DT substrate_NN buffer_NN solution_NN ,_,
          Bz-_NNP Pro-_NNP Phe-_NNP Arg-paranitroanilide_NNP ,_, (_( Sigma_NNP Chemical_NNP )_) was_VBD
          added_VBN to_TO each_DT well_RB ._. Cleavage_NNP of_IN the_DT substrate_NN was_VBD
          monitored_VBN by_IN measuring_VBG the_DT A_DT 
          405_CD over_IN time_NN ._. The_DT cysteine_NN protease_NN
          specific_JJ inhibitor_NN ,_, E_NNP 64_CD (_( Sigma_NNP )_) ,_, was_VBD included_VBN in_IN parallel_JJ
          assays_NNS at_IN a_DT concentration_NN of_IN 1_CD μM_NN to_TO determine_VB if_IN all_DT the_DT
          enzymatic_JJ activity_NN being_VBG measured_VBN could_MD be_VB attributed_VBN to_TO
          the_DT presence_NN of_IN a_DT cysteine_NN protease_NN ._.
        
        
          Binding_NNP assay_NN for_IN fibrinogen_NN
          The_DT ability_NN of_IN bacteria_NNS to_TO bind_NN fibrinogen_NN was_VBD
          determined_VBN by_IN their_PRP$ ability_NN to_TO bind_NN the_DT specific_JJ
          radiolabeled_JJ ligand_NN ._. Human_JJ fibrinogen_NN was_VBD radiolabeled_JJ
          with_IN 125_CD I_PRP (_( Amersham_NNP ,_, Chicago_NNP ,_, IL_NNP )_) using_VBG Iodobeads_NNP
          (_( Pierce_NNP ,_, Rockford_NNP ,_, IL_NNP )_) as_IN described_VBN [_NN 48_CD ]_NN ._. Different_JJ
          numbers_NNS of_IN bacteria_NNS were_VBD incubated_JJ with_IN 20_CD ,_, 000_CD cpm_NN of_IN
          125_CD I_PRP labeled_VBD fibrinogen_NN for_IN 60_CD min_NN at_IN 37_CD °_NN C_NNP ._. The_DT bacteria_NNS
          were_VBD pelleted_JJ by_IN centrifugation_NN at_IN 5_CD ,_, 000_CD ×_NN g_SYM for_IN 20_CD min_NN
          and_CC washed_VBN twice_RB with_IN 2_CD ml_NN of_IN 50_CD mM_NN veronal_NN buffer_NN pH_NN
          7_CD ._. 35_CD ,_, containing_VBG 0_CD ._. 15_CD M_NNP NaCl_NNP and_CC 0_CD ._. 1_CD %_NN gelatin_NN ._. The_DT
          radioactivity_NN associated_VBN with_IN the_DT bacterial_JJ pellet_NN was_VBD
          quantified_VBN in_IN a_DT Beckman_NNP 5500_CD B_NNP automatic_JJ gamma_NN counter_NN
          (_( Beckman_NNP ,_, Fullerton_NNP CA_NNP )_) ._.
        
      
    
  
